Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | YAP1 | P46937 | 3/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23818647 | 0.90 | CYP3A4 (0.37) | CYP3A4TSHRALDH1A1MEN1MAPT | |
| SCHEMBL23819269 | 0.87 | CYP3A4 (0.35) | CYP3A4TSHRALDH1A1MEN1MAPT | |
| SCHEMBL26290315 | 0.86 | POLRMT (0.36) | CYP3A4TSHRALDH1A1MEN1MAPT | |
| SCHEMBL26282930 | 0.86 | POLRMT (0.36) | CYP3A4TSHRALDH1A1MEN1MAPT | |
| SCHEMBL23818878 | 0.86 | CYP3A4 (0.32) | CYP3A4 | |
| SCHEMBL26276636 | 0.85 | POLRMT (0.36) | CYP3A4TSHRALDH1A1MEN1MAPT | |
| SCHEMBL26290301 | 0.84 | CYP3A4 (0.34) | CYP3A4TSHRALDH1A1MEN1MAPT | |
| SCHEMBL23819115 | 0.84 | CYP3A4 (0.33) | CYP3A4TSHRALDH1A1MEN1MAPT | |
| SCHEMBL26290110 | 0.84 | CYP3A4 (0.37) | CYP3A4TSHRALDH1A1MEN1MAPT | |
| SCHEMBL23803444 | 0.83 | ITGB3 (0.36) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | CYP3A4 435/4885TSHR 2321/4885ALDH1A1 1459/4885 |
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | CYP3A4 435/4885TSHR 2321/4885ALDH1A1 1459/4885 |
| US-11767337-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | CYP3A4 435/4885TSHR 2321/4885ALDH1A1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.